Shares of Cynosure Inc. (NASDAQ:CYNO) rose 3.6% during mid-day trading on Tuesday . The company traded as high as $54.01 and last traded at $53.87, with a volume of 107,306 shares. The stock had previously closed at $52.00.

CYNO has been the subject of a number of recent analyst reports. Zacks Investment Research downgraded Cynosure from a “hold” rating to a “sell” rating in a report on Tuesday, June 28th. Leerink Swann reissued a “buy” rating on shares of Cynosure in a report on Wednesday, April 27th. Maxim Group boosted their target price on Cynosure from $52.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday, April 26th. Stifel Nicolaus reissued a “buy” rating and issued a $62.00 target price (up from $57.00) on shares of Cynosure in a report on Wednesday, July 27th. Finally, Northland Securities set a $60.00 target price on Cynosure and gave the company a “buy” rating in a report on Wednesday, July 27th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $59.17.

The company has a market capitalization of $1.27 billion and a PE ratio of 63.35. The company’s 50 day moving average is $51.01 and its 200-day moving average is $45.62.

Cynosure (NASDAQ:CYNO) last announced its quarterly earnings results on Tuesday, July 26th. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.07. The company earned $110.30 million during the quarter, compared to analyst estimates of $101.31 million. During the same quarter in the prior year, the company posted $0.30 earnings per share. The firm’s revenue for the quarter was up 31.8% on a year-over-year basis. On average, analysts predict that Cynosure Inc. will post $1.34 earnings per share for the current year.

In related news, CFO Timothy W. Baker sold 12,451 shares of the stock in a transaction on Friday, May 13th. The stock was sold at an average price of $46.60, for a total value of $580,216.60. Following the completion of the sale, the chief financial officer now directly owns 2,042 shares in the company, valued at approximately $95,157.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Douglas J. Delaney sold 12,299 shares of the stock in a transaction on Friday, May 13th. The shares were sold at an average price of $46.60, for a total value of $573,133.40. Following the completion of the sale, the vice president now owns 2,042 shares of the company’s stock, valued at $95,157.20. The disclosure for this sale can be found here.

Several hedge funds have made changes to their positions in CYNO. California State Teachers Retirement System increased its stake in shares of Cynosure by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 41,020 shares of the company’s stock valued at $1,832,000 after buying an additional 646 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Cynosure by 7.3% in the fourth quarter. Rhumbline Advisers now owns 29,195 shares of the company’s stock valued at $1,304,000 after buying an additional 1,980 shares in the last quarter. Lapides Asset Management LLC increased its stake in shares of Cynosure by 6.4% in the fourth quarter. Lapides Asset Management LLC now owns 58,500 shares of the company’s stock valued at $2,613,000 after buying an additional 3,500 shares in the last quarter. Principal Financial Group Inc. increased its stake in shares of Cynosure by 9.0% in the fourth quarter. Principal Financial Group Inc. now owns 156,189 shares of the company’s stock valued at $6,977,000 after buying an additional 12,845 shares in the last quarter. Finally, Argent Capital Management LLC increased its stake in shares of Cynosure by 18.1% in the fourth quarter. Argent Capital Management LLC now owns 92,025 shares of the company’s stock valued at $4,111,000 after buying an additional 14,075 shares in the last quarter.

Cynosure Inc (Cynosure) develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve gynecologic health.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.